Mode
Text Size
Log in / Sign up

Hospital treatment for heroin use disorder reduced inflammatory markers and addiction scores in a prospective cohort.

Hospital treatment for heroin use disorder reduced inflammatory markers and addiction scores in a pr…
Photo by Cht Gsml / Unsplash
Key Takeaway
Note that treatment in this cohort reduced inflammatory markers and symptom scores, but duration of use and high neopterin predicted poorer outcomes.

This prospective observational cohort study investigated neurotoxic processes and psychiatric symptoms in patients with heroin use disorder who sought treatment at a hospital, compared against a healthy control group. The specific sample size was not reported, and the study phase was not detailed in the available data. The primary focus was on neurotoxic processes, while secondary outcomes included levels of neopterin, tryptophan, kynurenine, and various cytokines, as well as Addiction Profile Index and Symptom Checklist-90-Revised scores.

Following treatment, the heroin use disorder group demonstrated a statistically significant decrease in neopterin levels (p = 0.021) and tumor necrosis factor-alpha (TNF-α) levels (p < 0.05). In contrast, no significant changes were observed for interleukin-6 (IL-6) and interferon-gamma (IFN-γ) levels (p > 0.05). Treatment was also associated with a marked decrease in Addiction Profile Index (API-K) total scores (p < 0.001). Improvements were noted in Symptom Checklist-90-Revised general symptom level and subscales, although specific p-values for these outcomes were not reported.

Factors negatively affecting treatment success were identified, with the duration of use and high baseline neopterin levels emerging as the strongest predictors (p = 0.028 and p = 0.020, respectively). Safety data, including adverse events, tolerability, and discontinuations, were not reported. The study limitations include the lack of reported sample size, follow-up duration, and specific p-values for some secondary outcomes, which restricts the precision of the effect estimates.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
AimThis study investigated the effects of tryptophan (TRP) metabolism, kynurenine pathway (KP) and neopterin levels in heroin use disorder (HUD) in relation to neurotoxicity, treatment processes and psychiatric recovery.MethodThe study groups consisted of patients with HUD who sought treatment at the hospital and received treatment, and a healthy control (C) group. The levels of neopterin, tryptophan and kynurenine in the participants’ serum were determined, and the pre- and post-treatment results in the groups were compared with the controls.ResultsNeopterin levels, reflecting immune system activation, were observed to decrease in HUD group after treatment (p = 0.021). Similarly, a decrease in levels of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine, was also detected after treatment (p < 0.05). However, changes in interleukin-6 (IL-6) and interferon-gamma (IFN-γ) levels were not found to be significant (p > 0.05). The total scores of the Addiction Profile Index (API-K), which measures the severity of addiction, decreased significantly after treatment (p < 0.001). At the same time, improvement was observed in the general symptom level (GSI) and all subscales (including depression, anxiety, obsessive-compulsive disorders, and somatization) of the Symptom Checklist-90-Revised (SCL-90-R) scale, which assesses general psychopathology. Regression analyses revealed that the two strongest factors negatively affecting treatment success in the HUD group were duration of use (p = 0.028) and high neopterin levels (p = 0.020).ConclusionThis study highlights the critical role of immunological and neuroinflammatory processes in the success of HUD treatment. The findings indicate that biochemical recovery progresses in parallel with psychiatric recovery during treatment, and that changes in the KYN/TRP ratio and IL-6 levels have strong diagnostic and prognostic value. Neopterin, kynurenine, and tryptophan, on the other hand, have moderate prognostic value.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.